Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms

被引:2
|
作者
Neculae, Gabriela [1 ,2 ]
Adam, Robert [1 ,2 ]
Jercan, Andreea [2 ,3 ]
Badelita, Sorina [3 ]
Tjahjadi, Catherina [4 ]
Draghici, Mirela [5 ]
Stan, Claudiu [6 ]
Bax, Jeroen J. [4 ]
Popescu, Bogdan A. [1 ,2 ]
Marsan, Nina Ajmone [4 ]
Coriu, Daniel [2 ,3 ]
Jurcut, Ruxandra [7 ,8 ]
机构
[1] Prof Dr CC Iliescu Emergency Inst Cardiovasc Dis, Expert Ctr Rare Cardiovasc Dis, Bucharest, Romania
[2] Carol Davila Univ Med & Pharm, Bucharest, Romania
[3] Fundeni Clin Inst, Dept Hematol, Bucharest, Romania
[4] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands
[5] Fundeni Clin Inst, Dept Neurol, Bucharest, Romania
[6] Fundeni Clin Inst, Dept Nucl Med, Bucharest, Romania
[7] Carol Davila Univ Med & Pharm, Expert Ctr Rare Cardiovasc Dis, Prof Dr CC Iliescu Emergency Inst Cardiovasc Dis, Bucharest, Romania
[8] Carol Davila Univ Med & Pharm, Euroecholab, Prof Dr CC Iliescu Emergency Inst Cardiovasc Dis, Bucharest, Romania
来源
ESC HEART FAILURE | 2024年 / 11卷 / 05期
关键词
AL amyloidosis; ATTR amyloidosis; Cardiac amyloidosis; Diagnostic score; Myocardial deformation; CONSENSUS DOCUMENT; AL AMYLOIDOSIS; DIAGNOSIS; ECHOCARDIOGRAPHY; STANDARDIZATION; DYSFUNCTION; BIOMARKERS; PROGNOSIS;
D O I
10.1002/ehf2.14852
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Systemic amyloidosis represents a heterogeneous group of diseases resulting from amyloid fibre deposition. The purpose of this study is to establish a differential diagnosis algorithm targeted towards the two most frequent subtypes of CA. Methods and results We prospectively included all consecutive patients with ATTR and AL evaluated between 2018 and 2022 in two centres in a score derivation cohort and a different validation sample. All patients had a complete clinical, biomarker, electrocardiographic, and imaging evaluation. Confirmation of the final diagnosis with amyloid typing was performed according to the current international recommendations. The study population included 81 patients divided into two groups: ATTR (group 1, n = 32: 28 variant and 4 wild type) and AL (group 2, n = 49). ATTR patients were younger (50.7 +/- 13.9 vs. 60.2 +/- 7.3 years, P = 0.0001), and significantly different in terms of NT-proBNP [ATTR: 1472.5 ng/L (97-4218.5) vs. AL 8024 ng/L (3058-14 069) P = 0.001], hs-cTn I [ATTR: 10 ng/L (4-20) vs. AL 78 ng/L (32-240), P = 0.0002], GFR [ATTR 95.4 mL/min (73.8-105.3) vs. AL: 68.4 mL/min (47.8-87.4) P = 0.003]. At similar left ventricular (LV) wall thickness and ejection fraction, the ATTR group had less frequently pericardial effusion (ATTR: 15% vs. AL: 33% P = 0.0027), better LV global longitudinal strain (ATTR: -13.1% +/- 3.5 vs. AL: -9.1% +/- 4.3 P = 0.04), RV strain (ATTR: -21.9% +/- 6.2 vs. AL: -16.8% +/- 6 P = 0.03) and better reservoir function of the LA strain (ATTR: 22% +/- 12 vs. AL: 13.6% +/- 7.8 P = 0.02). Cut-off points were calculated based on the Youden method. We attributed to 2 points for parameters having an AUC > 0.75 (NT-proBNP AUC 0.799; hs-cTnI AUC 0.87) and 1 point for GFR (AUC 0.749) and TTE parameters (GLS AUC 0.666; RV FWS AUC 0.649, LASr AUC 0.643). A score of equal or more than 4 points has been able to differentiate between AL and ATTR (sensitivity 80%, specificity 62%, AUC = 0.798). The differential diagnosis score system was applied to the validation cohort of 52 CA patients showing a sensitivity of 81% with specificity of 77%. Conclusions CA is a complex entity and requires extensive testing for a positive diagnosis. This study highlights a series of non-invasive checkpoints, which can be useful in guiding the decision-making process towards a more accurate and rapid differential diagnosis.
引用
收藏
页码:2481 / +
页数:977
相关论文
共 50 条
  • [31] Sex-related differences in clinical presentation and outcome of patients with cardiac transthyretin amyloidosis and light chain amyloidosis
    Zampieri, Mattia
    Argiro, Alessia
    Allinovi, Marco
    Tassetti, Luigi
    Zocchi, Chiara
    Gabriele, Martina
    Andrei, Valentina
    Fumagalli, Carlo
    Di Mario, Carlo
    Tomberli, Alessia
    Olivotto, Iacopo
    Perfetto, Federico
    Cappelli, Francesco
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL G)
  • [32] Sex-related differences in clinical presentation and outcome of patients with cardiac transthyretin amyloidosis and light chain amyloidosis
    Zampieri, Mattia
    Argiro, Alessia
    Allinovi, Marco
    Tassetti, Luigi
    Zocchi, Chiara
    Gabriele, Martina
    Andrei, Valentina
    Fumagalli, Carlo
    Di Mario, Carlo
    Tomberli, Alessia
    Olivotto, Iacopo
    Perfetto, Federico
    Cappelli, Francesco
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0G)
  • [33] Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
    Zhang, Kathleen W.
    Stockerl-Goldstein, Keith E.
    Lenihan, Daniel J.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2019, 4 (03): : 438 - 448
  • [34] Diagnosis of transthyretin versus light chain cardiac amyloidosis by apical sparing strain ratio in patients with clinically suspected disease
    Zhang, K. W.
    Zhang, R.
    Soyama, Y.
    Karmpalioti, M.
    Lenihan, D. J.
    Gorcsan, J.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1675 - 1675
  • [35] Demographics and Complications According to Amyloidosis Subtypes Light Chain Amyloidosis and Hereditary Transthyretin Amyloidosis
    Ma, Jennifer
    Ream, Sarah
    Rodriguez, Tayana
    Sarabia-Gonzalez, Alejandro
    Alvarado, Luis
    Dwivedi, Alok
    Mukherjee, Debabrata
    CIRCULATION, 2021, 144
  • [36] Differences between AL and transthyretin cardiac amyloidosis: A comparison of the echocardiographic morphological variables
    Abrantes, A. Ana
    Garcia, A. B.
    De Oliveira, C. Simoes
    Martins, A. M.
    Silva, B. Valente
    Da Silva, P. Alves
    Brito, J.
    Gregorio, C.
    Fonseca, J.
    Raposo, M.
    Placido, R.
    Almeida, A. G.
    Pinto, F. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 363 - 363
  • [37] More Extensive Left Ventricular Hypertrophy in Transthyretin-Type Cardiac Amyloidosis as Compared to Primary Light-Chain Cardiac Amyloidosis
    Appelbaum, Evan
    Harrigan, Caitlin
    Manning, Warren J.
    Ruberg, Frederick L.
    Gibson, Michael
    Skinner, Martha
    Tripp, Kenneth J.
    Packman, Jeff
    Grogan, Donna
    CIRCULATION, 2008, 118 (18) : S600 - S600
  • [38] Novel echocardiographic pixel intensity quantification method for differentiating transthyretin cardiac amyloidosis from light chain cardiac amyloidosis and other phenocopies
    Slostad, Brody
    Appadurai, Vinesh
    Narang, Akhil
    Hale, Sarah
    Lehrer, Susan
    Kline, Adrienne
    Bavishi, Aakash
    Okwuosa, Ike
    Jankowski, Madeline
    Weinberg, Richard
    Kansal, Mayank
    Thomas, James D.
    Shah, Sanjiv
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2024, 25 (11) : 1601 - 1611
  • [39] Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis
    Papathanasiou, Maria
    Jakstaite, Aiste-Monika
    Oubari, Sara
    Siebermair, Johannes
    Wakili, Reza
    Hoffmann, Julia
    Carpinteiro, Alexander
    Hagenacker, Tim
    Thimm, Andreas
    Rischpler, Christoph
    Kessler, Lukas
    Rassaf, Tienush
    Luedike, Peter
    ESC HEART FAILURE, 2022, 9 (03): : 1740 - 1748
  • [40] Step-by-step typing for the accurate diagnosis of concurrent light chain and transthyretin cardiac amyloidosis
    Moriyama, Hidenori
    Kitakata, Hiroki
    Endo, Jin
    Ikura, Hidehiko
    Sano, Motoaki
    Tasaki, Masayoshi
    Sakai, Shunta
    Ueda, Mitsuharu
    Fukuda, Keiichi
    ESC HEART FAILURE, 2022, 9 (02): : 1474 - 1477